临床药师利用PDCA循环参与卵巢良性肿瘤临床路径管理的效果

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (38 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the methods and effect of clinical pharmacists′ participating in the clinical pathway management of ovarian benign tumors by PDCA circulation.Methods From November 2018 to October 2019, 120 inpatients with ovarian benign tumor who met the criteria of clinical pathway of ovarian benign tumor were selected as the study objects, according to the method of random number table, they were divided into the observation group and the control group, 60 cases in each group.The routine clinical pathway management of ovarian benign tumor was implemented in the control group, and the PDCA cycle clinical pathway management of clinical pharmacists was implemented in the observation group.The observation group was divided into the observation group 1 and the observation group 2 according to the different cycle, 30 cases in the each group.The first PDCA cycle was implemented in the observation group 1 (from November 2018 to April 2019), and the second PDCA cycle was implemented in the observation group 2 (from May to October 2019).The cost condition, auxiliary medication condition, rational use of prophylactic antibiotics and follow-up compliance of patients in the each group were recorded.Results There was no statistically significant difference in the length of hospital stay among the three groups (P＞0.05); the hospitalization cost of the observation group 2 was lower than that of the observation group 1 and the control group, and the differences were statistically significant (P＜0.05); there was no statistically significant difference in hospitalization expenses between the observation group 1 and the control group (P＞0.05); in terms of drug costs, the control group＞observation 1 group＞observation 2 groups, the differences among the three groups were statistically significant (P＜0.05).Observation group 1 and observation group 2 had fewer auxiliary medication costs and medication varieties than the control group, and the differences were statistically significant (P＜0.05); and observation 2 groups had fewer auxiliary medication costs and medication varieties than observation 1 group, the differences were statistically significant (P＜0.05).The reasonable rate of antimicrobial use in observation group 1 and observation group 2 was all higher than that in the control group, and the differences were statistically significant (P＜0.05); follow-up compliance rate of observation group 1 was higher than that in the the control group, the difference was statistically significant (P＜0.05); there was no statistically significant difference between the observation group 2 and the control group in follow-up compliance rate (P＞0.05); there was no statistically significant difference between the observation group 1 and the observation group 2 in the reasonable rate of antimicrobial use and follow-up compliance rate(P＞0.05).Conclusion The PDCA method to continuously optimize the clinical pharmacist′s participation in clinical path management can better standardize clinical medication and ensure patients′ safe medication.After the second cycle, hospitalization costs, drug costs, auxiliary drug costs, and the number of drug types have all been further optimized, showing that continuous optimization management is essential.

Key words： Clinical pharmacists Ovarian benign tumor Clinical pathway PDCA circulation method

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHONG Mei-gong
	TAN Wen-qiang
	WU Zhuo-jian
	LIANG Fa-liang

Cite this article:

ZHONG Mei-gong,TAN Wen-qiang,WU Zhuo-jian, et al. Effect of clinical pharmacists′ participation in clinical pathway management of ovarian benign tumor by PDCA circulation[J]. 中国当代医药, 2020, 27(22): 181-184.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I22/181

[1]	李敏.妇产科卵巢良性肿瘤临床疗效分析[J].世界最新医学信息文摘，2018，18（41）：79-80.
[2]	Mohamed AA，Al-Hussaini TK，Fathalla MM，et al.The impact of excision of benign nonendometriotic ovarian cysts on ovarian reserve：a systematic review[J].Am J Obstet Gynecol，2016，215（2）：169-176.
[3]	邓杨林，吴晖，普鑫，等.昆明医科大学第一附属医院临床路径药学评价体系的建立与应用[J].中国医院用药评价与分析，2019，19（1）：83-86.
[4]	卫生部医政司.妇科临床路径[M].北京：人民卫生出版社，2012：7-11.
[5]	中华医学会.临床诊疗指南-妇产科学分册[M].北京：人民卫生出版社，2007：82-91.
[6]	卫生部，国家中医药管理局，总后卫生部.抗菌药物临床应用指导原则[J].中国中医药现代远程教育，2004，2（11）：10-11.
[7]	韩凤昭，李振知，杨文华.临床药师参与骨科临床路径中抗凝治疗的探索与思考[J].中南药学，2017，15（8）：1164-1167.
[8]	张莉，胡淼，王义俊.临床药师参与子宫肌瘤手术临床路径药学服务的方法及效果分析[J].中国医院药学杂志，2019，39（23）：2441-2444.
[9]	魏丽娟，郑平，王静.精细化临床路径管理在慢性阻塞性肺疾病急性加重患者抗菌药物治疗中的应用效果[J].中华全科医师杂志，2019，18（9）：842-846.
[10]	章考飞，凌艺兰，汪峰，等.浅谈药剂科对医院不合理用药的药学干预[J].安徽医药，2019，23（2）：390-394.
[11]	亓志刚，贺晴，陆一，等.某院泌尿外科围手术期预防用抗菌药物管控模式的建立及成效[J].中国药房，2019，30（15）：2022-2026.
[12]	彭晓凤，冯力，王玉，李斌.临床药师利用PDCA 法参与脑梗死临床路径效果评价[J].重庆医学，2018，47（17）：2303-2305，2308.
[13]	张磊，刘凯，徐丹，等.四川大学华西医院基于PDCA 的临床路径入径率管理实践[J].中国循证医学杂志，2018，18（9）：87-92.
[14]	王飞，张春燕，席辉，等.PDCA 循环在提高临床路径覆盖率中的应用[J].中国卫生产业，2019，16（23）：1-2.
[15]	朱江华，李玲，汤卓红，等.PDCA 循环在我院Ⅰ类切口手术抗菌药物预防使用中的应用[J].广东药科大学学报，2019，35（4）：561-564，568.
[16]	刘少华，兰艳，王雨来，等.运用PDCA 循环法规范抗菌药物Ⅰ类切口预防性使用[J].中国药业，2019，28（23）：91-93.
[17]	杨静谟，张波，孙言才.某肿瘤专科医院Ⅰ类切口手术围手术期预防用抗菌药物合理性点评及经济性分析[J].中国临床药理学与治疗学，2019，24（7）：821-825.